BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 30466751)

  • 1. Patterns of mutations in TP53 mutated AML.
    Welch JS
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of p53 in regulation of hematopoiesis in health and disease.
    Barajas S; Cai W; Liu Y
    Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
    Kojima K
    Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of
    Middeke JM; Teipel R; Röllig C; Stasik S; Zebisch A; Sill H; Kramer M; Scholl S; Hochhaus A; Jost E; Brümmendorf TH; Naumann R; Steffen B; Serve H; Altmann H; Kunzmann V; Einsele H; Parmentier S; Schaich M; Burchert A; Neubauer A; Schliemann C; Berdel WE; Sockel K; Stölzel F; Platzbecker U; Ehninger G; Bornhäuser M; Schetelig J; Thiede C;
    Leuk Lymphoma; 2021 Jun; 62(6):1432-1440. PubMed ID: 33399480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
    Daver NG; Maiti A; Kadia TM; Vyas P; Majeti R; Wei AH; Garcia-Manero G; Craddock C; Sallman DA; Kantarjian HM
    Cancer Discov; 2022 Nov; 12(11):2516-2529. PubMed ID: 36218325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and characteristics of patients with
    Bewersdorf JP; Shallis RM; Gowda L; Wei W; Hager K; Isufi I; Kim TK; Pillai MM; Seropian S; Podoltsev NA; Gore SD; Siddon AJ; Zeidan AM
    Leuk Lymphoma; 2020 Sep; 61(9):2180-2190. PubMed ID: 32362171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
    Kim K; Maiti A; Loghavi S; Pourebrahim R; Kadia TM; Rausch CR; Furudate K; Daver NG; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Tang G; Ravandi F; Kantarjian HM; DiNardo CD; Konopleva MY
    Cancer; 2021 Oct; 127(20):3772-3781. PubMed ID: 34255353
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ball S; Loghavi S; Zeidan AM
    Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    George B; Kantarjian H; Baran N; Krocker JD; Rios A
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
    DiGennaro J; Sallman DA
    Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and new treatment approaches in TP53 mutated AML.
    Hunter AM; Sallman DA
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
    Yan B; Claxton D; Huang S; Qiu Y
    Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
    Venugopal S; Loghavi S
    Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Santini V; Stahl M; Sallman DA
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424
    [No Abstract]   [Full Text] [Related]  

  • 19. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
    Duong VH; Ruppert AS; Mims AS; Borate U; Stein EM; Baer MR; Stock W; Kovacsovics T; Blum W; Arellano ML; Schiller GJ; Olin RL; Foran JM; Litzow MR; Lin TL; Patel PA; Foster MC; Redner RL; Al-Mansour Z; Cogle CR; Swords RT; Collins RH; Vergilio JA; Heerema NA; Rosenberg L; Yocum AO; Marcus S; Chen T; Druggan F; Stefanos M; Gana TJ; Shoben AB; Druker BJ; Burd A; Byrd JC; Levine RL; Boyiadzis MM
    Cancer; 2023 Aug; 129(15):2308-2320. PubMed ID: 37078412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
    Zhu G; Cai J; Zhong H
    Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.